Marianne D Sadar1. 1. Genome Sciences Centre, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC, V5Z 1L3, Canada. msadar@bcgsc.ca
Abstract
OBJECTIVES: Current treatments for localized prostate cancer include brachytherapy, external beam radiation, surgery, and active surveillance. Unfortunately, 20-40% of prostate cancer patients will experience recurrence and require hormonal therapies. These therapies involve androgen ablation by chemical or surgical castration and application of antiandrogens. Hormonal therapy is initially effective, but will inevitably fail and the disease will progress to lethal castration-resistant prostate cancer (CRPC) from which patients succumb within 2 years. CRPC is considered to be dependent on transcriptionally active androgen receptors (AR). This article reviews recent advances in the discovery and development of small molecule inhibitors of AR. METHODS: A PubMed database search was performed for articles focused on small molecule inhibitors of AR for potential development for the treatment of prostate cancer. Compounds with broad effects on other pathways were not included. RESULTS: Currently, there are several novel antiandrogens being tested in the clinic that have improved affinity for the AR and work by different mechanisms to the current battery of approved antiandrogens that are discussed. Small molecule inhibitors that interact with regions other than the AR ligand-binding pocket have been also been discovered. These small molecules include allosteric inhibitors of the LBD, compounds that alter AR conformation, and antagonists to the AR NTD and are highlighted. CONCLUSIONS: CRPC is dependent upon transcriptionally active AR. Survival improvement may be achieved by complete blockade of all AR activity using novel small molecule inhibitors with unique mechanisms of action.
OBJECTIVES: Current treatments for localized prostate cancer include brachytherapy, external beam radiation, surgery, and active surveillance. Unfortunately, 20-40% of prostate cancerpatients will experience recurrence and require hormonal therapies. These therapies involve androgen ablation by chemical or surgical castration and application of antiandrogens. Hormonal therapy is initially effective, but will inevitably fail and the disease will progress to lethal castration-resistant prostate cancer (CRPC) from which patients succumb within 2 years. CRPC is considered to be dependent on transcriptionally active androgen receptors (AR). This article reviews recent advances in the discovery and development of small molecule inhibitors of AR. METHODS: A PubMed database search was performed for articles focused on small molecule inhibitors of AR for potential development for the treatment of prostate cancer. Compounds with broad effects on other pathways were not included. RESULTS: Currently, there are several novel antiandrogens being tested in the clinic that have improved affinity for the AR and work by different mechanisms to the current battery of approved antiandrogens that are discussed. Small molecule inhibitors that interact with regions other than the AR ligand-binding pocket have been also been discovered. These small molecules include allosteric inhibitors of the LBD, compounds that alter AR conformation, and antagonists to the AR NTD and are highlighted. CONCLUSIONS: CRPC is dependent upon transcriptionally active AR. Survival improvement may be achieved by complete blockade of all AR activity using novel small molecule inhibitors with unique mechanisms of action.
Authors: Shihua Sun; Cynthia C T Sprenger; Robert L Vessella; Kathleen Haugk; Kathryn Soriano; Elahe A Mostaghel; Stephanie T Page; Ilsa M Coleman; Holly M Nguyen; Huiying Sun; Peter S Nelson; Stephen R Plymate Journal: J Clin Invest Date: 2010-07-19 Impact factor: 14.808
Authors: Dana Rathkopf; Glenn Liu; Michael A Carducci; Mario A Eisenberger; Aseem Anand; Michael J Morris; Susan F Slovin; Yasutsuna Sasaki; Shunji Takahashi; Seiichiro Ozono; Nga Kit Eliza Fung; Shinta Cheng; Jinping Gan; Marco Gottardis; Mary T Obermeier; Jyotsna Reddy; Steven Zhang; Blisse J Vakkalagadda; Leila Alland; George Wilding; Howard I Scher Journal: Clin Cancer Res Date: 2010-12-03 Impact factor: 12.531
Authors: Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers Journal: Science Date: 2009-04-09 Impact factor: 47.728
Authors: James D Joseph; Bryan M Wittmann; Mary A Dwyer; Huaxia Cui; Delita A Dye; Donald P McDonnell; John D Norris Journal: Proc Natl Acad Sci U S A Date: 2009-07-02 Impact factor: 11.205
Authors: Marianne D Sadar; David E Williams; Nasrin R Mawji; Brian O Patrick; Thamrin Wikanta; Ekowati Chasanah; Hari Eko Irianto; Rob Van Soest; Raymond J Andersen Journal: Org Lett Date: 2008-10-04 Impact factor: 6.005
Authors: Jeremy O Jones; Eric C Bolton; Yong Huang; Clementine Feau; R Kiplin Guy; Keith R Yamamoto; Byron Hann; Marc I Diamond Journal: Proc Natl Acad Sci U S A Date: 2009-04-10 Impact factor: 11.205
Authors: Marie C Hupe; M Raschid Hoda; Friedemann Zengerling; Sven Perner; Axel S Merseburger; Marcus V Cronauer Journal: World J Urol Date: 2018-06-22 Impact factor: 4.226
Authors: Wolfgang Streicher; Manuel Luedeke; Anca Azoitei; Friedemann Zengerling; Alexander Herweg; Felicitas Genze; Mark G Schrader; Andres J Schrader; Marcus V Cronauer Journal: PLoS One Date: 2014-06-02 Impact factor: 3.240